119th Congress
H.R. 10887
Protecting Consumer Access to Generic Drugs Act of 2026
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Seth Magaziner(D-RI)
- Introduced
- Oct 22, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce;House Committee on the Judiciary
- Official text
- Introduced in House · Congress.gov page
Cosponsors (0)
No cosponsors.
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Official title: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Latest action(Oct 22, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Roll-call votes
No recorded votes on this bill.
Actions
- Oct 22, 2026 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. - Oct 22, 2026
Introduced in House